After menopause, estrogen no longer comes primarily from the ovaries. Instead, it’s produced in smaller amounts by fat tissue, bone, blood vessels, the brain, and other sites throughout the body. The adrenal glands also play a key role by supplying the raw materials (androgens) that these tissues convert into estrogen. The result is a fundamentally different system: rather than one central organ flooding the bloodstream with estrogen, dozens of local tissue sites make small quantities for their own use.
The Shift From Ovaries to Fat and Other Tissues
Before menopause, the ovaries are estrogen headquarters. They produce estradiol, the strongest form of estrogen, and release it into the bloodstream where it travels to tissues all over the body. After menopause, the ovaries essentially stop making estradiol. But the body doesn’t lose the ability to make estrogen entirely. It just relocates production.
The new primary source is adipose (fat) tissue, particularly in the belly, breasts, and thighs. Fat cells contain an enzyme called aromatase that converts androgens into estrogen. Bone-building cells, blood vessel walls, and several regions of the brain also contain aromatase and produce their own local estrogen. The critical difference is that this estrogen mostly stays local. It acts on the tissue that made it rather than circulating widely through the bloodstream. Researchers describe this as a shift from an endocrine system (hormones traveling through the blood) to a paracrine or intracrine one (hormones acting right where they’re made).
Where the Raw Materials Come From
Fat and bone cells can’t make estrogen from scratch. They need androgen precursors, which come from two places: the adrenal glands and, surprisingly, the ovaries themselves.
The adrenal glands, small organs sitting on top of each kidney, secrete androgens like DHEA and androstenedione. These circulate through the bloodstream and get picked up by tissues containing aromatase, which converts androstenedione into estrone, the dominant form of postmenopausal estrogen. DHEA acts as a reservoir of raw material that the body can draw on for years after menopause. During the menopausal transition, levels of DHEA and related androgens actually rise, providing a buffer of substrate for this peripheral conversion.
The postmenopausal ovary also contributes. While it stops producing estradiol, it continues secreting testosterone and some androstenedione. Research measuring hormone levels in the ovarian veins of postmenopausal women found a clear gradient, with significantly higher testosterone concentrations coming directly from the ovary compared to the rest of the circulation. This contribution persists for at least 10 years after menopause, making the ovaries a meaningful, ongoing source of androgen raw material even when they’ve stopped making estrogen directly.
Estrone Replaces Estradiol
The body makes three main forms of estrogen: estradiol (E2), estrone (E1), and estriol (E3). Before menopause, estradiol dominates. It’s the most potent form, responsible for the bulk of estrogen’s effects on the heart, bones, brain, and reproductive system.
After menopause, estrone takes over as the primary circulating estrogen. It’s a weaker form, produced mainly in fat tissue from adrenal androstenedione. Postmenopausal estradiol levels drop below 10 pg/mL, while estrone levels typically range from 7 to 40 pg/mL. For comparison, premenopausal estradiol levels can reach 200 to 400 pg/mL during ovulation. So the total amount of circulating estrogen drops dramatically, and the type that remains is considerably less potent.
Why Body Fat Matters
Because fat tissue is the primary estrogen factory after menopause, body composition directly influences how much estrogen a postmenopausal woman produces. Women with a higher BMI have more aromatase activity and therefore convert more androgens into estrogen. Research shows a clear positive correlation: the higher a woman’s BMI, the more aromatase her fat tissue expresses. This relationship is even stronger in postmenopausal women than in premenopausal women.
This connection has real health implications in both directions. On one hand, the extra estrogen from fat tissue may offer some protection against bone loss and certain menopausal symptoms. On the other hand, it raises the risk of estrogen-sensitive breast cancer. The majority of breast cancers diagnosed after menopause are estrogen-dependent, and obesity is a well-established risk factor. The estrogen driving these cancers isn’t coming from the bloodstream in large quantities. It’s being produced locally, right within the breast fat tissue itself, where inflammation associated with larger fat cells further ramps up aromatase activity.
Surgical Menopause Changes the Equation
Women who have both ovaries surgically removed before natural menopause face a steeper hormone drop than women who go through menopause naturally. In natural menopause, the ovaries wind down gradually and continue contributing androgens for years afterward. Surgical removal eliminates both the residual androgen supply from the ovaries and any remaining trace estrogen production in one abrupt event.
The result is more severe vasomotor symptoms (hot flashes and night sweats), higher rates of mood changes, sleep problems, sexual dysfunction, and joint pain compared to natural menopause. These women still produce estrogen from fat tissue and other peripheral sites using adrenal androgens, but they lose the ovarian androgen contribution entirely, which can mean a meaningfully lower total estrogen level.
What Low Local Estrogen Means for Your Body
Even though the body continues making estrogen after menopause, the amounts are far smaller and the effects are localized rather than body-wide. This drop has well-documented consequences across several systems.
In bones, estrogen produced locally by bone-building cells helps maintain mineral density. When production falls short, the balance tips toward bone loss, which is why osteoporosis risk climbs after menopause. In the brain, locally produced estrogen supports cognitive function, and declining levels are linked to changes in memory and mood. In blood vessels, estrogen normally promotes flexibility, supports healthy cholesterol ratios, and keeps inflammation in check. After menopause, reduced estrogen contributes to stiffer arteries, impaired blood flow regulation, and a shift toward higher LDL cholesterol and lower HDL cholesterol. These vascular changes are a major reason cardiovascular disease risk rises sharply in the postmenopausal years.
The key insight is that after menopause, estrogen’s effects depend on what’s happening tissue by tissue rather than on a single blood level. A postmenopausal woman’s circulating estrogen may test very low, while estrogen activity inside her breast tissue or bones could be considerably higher, depending on local aromatase activity, body composition, and inflammation. This is why researchers increasingly view postmenopausal estrogen as a local phenomenon with whole-body consequences.